Pulse Biosciences (PLSE)
NASDAQ:PLSE
PLSE Stock Chart & Stats
$20.12
-$0.27(-1.46%)
At close: 4:00 PM EST
$20.12
-$0.27(-1.46%)
Day’s Range― - ―
52-Week Range$12.56 - $26.30
Previous CloseN/A
Volume31.18K
Average Volume (3M)189.63K
Market Cap
$1.29B
Enterprise Value$1.29B
Total Cash (Recent Filing)$80.73M
Total Debt (Recent Filing)$7.53M
Price to Earnings (P/E)―
Beta1.40
Next Earnings
May 07, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding67,989,075
10 Day Avg. Volume222,519
30 Day Avg. Volume189,626
Financial Highlights & Ratios
PEG Ratio-0.73
Price to Book (P/B)11.47
Price to Sales (P/S)2643.82
P/FCF Ratio-17.00
Enterprise Value/Market Cap1.01
Enterprise Value/Revenue3.70K
Enterprise Value/Gross Profit-1.81K
Enterprise Value/Ebitda-17.74
Forecast
1Y Price Target
$30.00Price Target Upside49.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.33
Revenue Forecast (FY)$3.23M
Bulls Say, Bears Say
Bulls Say
Robust Clinical Efficacy (nPulse AF)Consistently high procedural success and durable 12‑month outcomes materially de‑risk the core technology. Durable efficacy and safety data can drive clinician adoption, support favorable labeling and reimbursement, and sustain a durable competitive position in AF ablation markets.
Regulatory Progress & Pivotal TrialsSecuring multiple IDEs and moving into pivotal enrollment advances the firm along a defined regulatory pathway. Achieving these milestones would unlock commercial clearances, reduce technical/regulatory risk over months, and create scalable revenue channels once approvals and reimbursement align.
Expanding Intellectual Property EstateA rapidly growing patent portfolio strengthens barriers to entry around nsPFA technology, supports competitive differentiation, and enhances bargaining power for partnerships or licensing. Durable IP coverage can protect long‑term market share and justify strategic collaborations.
Bears Say
Minimal Revenue And Thin Gross MarginNominal product revenue and effectively zero gross margin show commercial traction is still nascent. Over the medium term, the company must materially scale installed base and consumable volumes to reach sustainable margins; failure to convert trials into repeatable sales will keep losses persistent.
Accelerating Cash BurnSignificantly higher operating cash outflows highlight a structural funding need while commercialization and pivotal trials consume capital. Persistent negative free cash flow increases dependency on external financing and can constrain execution if access to capital becomes limited or costly.
Funding Dependence And Commercialization Timing RiskReliance on future equity, partnerships or ATM programs creates dilution and execution uncertainty. Coupled with reimbursement and additional regulatory clearances taking multiple quarters, funding timing and structure could delay scale, hinder hiring, or force suboptimal commercial rollouts.
Pulse Biosciences News
PLSE FAQ
What was Pulse Biosciences’s price range in the past 12 months?
Pulse Biosciences lowest stock price was $12.56 and its highest was $26.30 in the past 12 months.
What is Pulse Biosciences’s market cap?
Pulse Biosciences’s market cap is $1.29B.
When is Pulse Biosciences’s upcoming earnings report date?
Pulse Biosciences’s upcoming earnings report date is May 07, 2026 which is in 21 days.
How were Pulse Biosciences’s earnings last quarter?
Pulse Biosciences released its earnings results on Feb 19, 2026. The company reported -$0.183 earnings per share for the quarter, beating the consensus estimate of -$0.265 by $0.082.
Is Pulse Biosciences overvalued?
According to Wall Street analysts Pulse Biosciences’s price is currently Undervalued.
Does Pulse Biosciences pay dividends?
Pulse Biosciences does not currently pay dividends.
What is Pulse Biosciences’s EPS estimate?
Pulse Biosciences’s EPS estimate is -0.27.
How many shares outstanding does Pulse Biosciences have?
Pulse Biosciences has 67,989,075 shares outstanding.
What happened to Pulse Biosciences’s price movement after its last earnings report?
Pulse Biosciences reported an EPS of -$0.183 in its last earnings report, beating expectations of -$0.265. Following the earnings report the stock price went down -14.593%.
Which hedge fund is a major shareholder of Pulse Biosciences?
Currently, no hedge funds are holding shares in PLSE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pulse Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$30.00 (49.11% Upside)
$30.00 (49.11% Upside)
Blogger Sentiment
Bullish
PLSE Sentiment 75%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 11.6K Shares
Last Quarter.
Last Quarter.
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-15.46%
12-Months-Change
Fundamentals
Return on Equity
-73.46%
Trailing 12-Months
Asset Growth
-28.30%
Trailing 12-Months
Company Description
Pulse Biosciences
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
PLSE Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed strong clinical and technology progress—IDE approvals, compelling early efficacy data with high 12‑month success rates, rapid procedure times, and substantial IP expansion—which materially de-risks key scientific and regulatory milestones. However, the financial picture remains early-stage: product revenue is still nominal, gross margin was effectively negligible in the quarter, operating losses persist, cash reserves declined substantially year-over-year, and broader commercialization hinges on additional regulatory clearances and reimbursement processes that may take multiple quarters. Overall, the narrative balances important clinical/strategic momentum against clear near-term financial and commercialization constraints.View all PLSE earnings summariesPLSE Stock 12 Month Forecast
Average Price Target
$30.00
▲(49.11% Upside)
Technical Analysis
Ownership Overview
73.34% Insiders
2.28% Mutual Funds
1.48% Other Institutional Investors
20.13% Public Companies and
Individual Investors